Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022
11:00am, Tuesday, 26'th Jul 2022 GlobeNewswire Inc.
PHILADELPHIA, July 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at
Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022
07:00am, Tuesday, 26'th Jul 2022
PHILADELPHIA, July 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at 8:
Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe
02:14pm, Tuesday, 28'th Jun 2022 Zacks Investment Research
Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of
Why Is Amicus Therapeutics (FOLD) Up 25.1% Since Last Earnings Report?
03:30pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
07:00am, Wednesday, 08'th Jun 2022
PHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcar
Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe
06:27pm, Tuesday, 31'st May 2022 Zacks Investment Research
Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.
Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe
03:49pm, Tuesday, 31'st May 2022
Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.
7 Biotech Stocks With Key Catalysts for May
06:35am, Wednesday, 11'th May 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on Investo
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates
06:36pm, Tuesday, 10'th May 2022 Zacks Investment Research
Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates
03:48pm, Tuesday, 10'th May 2022
Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amicus Therapeutics, Inc.'s (FOLD) CEO John Crowley on Q1 2022 Results - Earnings Call Transcript
01:34pm, Monday, 09'th May 2022
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Andrew Faughnan - Executive Director-Investor Relations John Crowley - Chairman an
CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results
01:15pm, Monday, 09'th May 2022 GlobeNewswire Inc.
1Q22 Galafold® Revenue Growth of 18.5% to $78.7M
Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
09:51am, Monday, 09'th May 2022
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25% and 2.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
07:48pm, Friday, 06'th May 2022 Zacks Investment Research
Aerie (AERI) misses on both earnings and revenues for the first quarter of 2022.
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
07:38pm, Friday, 06'th May 2022 Zacks Investment Research
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.
